Matinas BioPharma (MTNB) investor relations material

Executive summary

• Focused on advancing MAT2203 and LNC platform, with efforts to secure a partner for Phase 3 development and commercialization.

• Net loss for the nine months ended September 30, 2025 was $8.4M, a significant improvement from $15.8M in the prior year period.

• Operating expenses and R&D costs decreased sharply due to a pause in MAT2203 development and workforce reduction.

Financial highlights

• Cash and cash equivalents at September 30, 2025 were $5.4M, down from $7.3M at year-end 2024.

• Net loss attributable to common shareholders for the nine months was $9.1M, including a $0.6M deemed dividend from a warrant exchange.

• No revenue reported; total operating expenses for the nine months were $5.4M, down from $16.1M year-over-year.

• R&D expenses for the nine months were $0.1M, down from $9.1M in the prior year.

• General and administrative expenses for the nine months were $5.3M, down from $7.1M year-over-year.

Outlook and guidance

• Expenses expected to remain lower until a partnership or transaction is secured to fund Phase 3 MAT2203 trial.

• Substantial doubt exists about the ability to continue as a going concern beyond the next 12 months without additional funding.

• Plans to seek additional capital through equity, debt, or strategic transactions.